John Park, MD

Professor

John W. Park, MD, is Professor of Medicine in the Division of Hematology/Oncology at University of California, San Francisco (UCSF) School of Medicine, and Director of Novel Therapeutics in Breast Oncology at the UCSF Comprehensive Cancer Center. Dr. Park received his AB degree at Harvard College, and MD degree at Stanford University School of Medicine. Dr. Park completed his residency training in Internal Medicine at UCLA Medical Center, and fellowship training in Hematology/Oncology at UCSF Medical Center. Dr. Park was also a visiting scientist at Genentech, Inc., where he worked on the development of trastuzumab (HerceptinTM).

Dr. Park has been the recipient of multiple honors and awards, including the ASCO Young Investigator Award, the Career Development Award from the US Department of Defense Breast Cancer Research Program, and Top Doctor from US News & World Report. Dr. Park has authored over 130 published papers and authored or edited 18 books/book chapters on cancer research. Dr. Park is also an inventor with multiple US patents relating to new cancer treatments.

Dr. Park’s major research interests include novel targeted cancer therapeutics and new cancer biomarkers. Dr. Park’s research is well known for its discovery and development of targeted therapeutics using nanoparticle/liposome/immunoliposome technologies. These include nanoliposomal irinotecan (nal-IRI, OnivydeTM), which received US FDA approval in 2015, as well as novel immunoliposome drugs. Dr. Park is also a noted expert in the field of circulating tumor cell and biomarker studies.

Publications

  1. Silverstein J, Wright F, Stanfield D, Chien AJ, Wong JM, Park JW, Blanco A, Van Loon K, Atreya CE. Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series. The oncologist 2024. PMID: 38856325


  2. Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. NPJ breast cancer 2024. PMID: 38409268


  3. Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast cancer research and treatment 2023. PMID: 36689092


  4. Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ breast cancer 2021. PMID: 34489453


  5. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. Journal of the National Cancer Institute 2020. PMID: 32770247


  6. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA oncology 2020. PMID: 32701140


  7. Magbanua MJM, Savenkov O, Asmus EJ, Ballman K, Scott JH, Park JW, Dickler M, Partridge AH, Carey LA, Winer E, Rugo HS. Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32586939


  8. Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast cancer research and treatment 2019. PMID: 31172405


  9. Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson A, Van't Veer LJ, Essermann L, Park JW. Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predict adverse outcome in early breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2019. PMID: 31142502


  10. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ breast cancer 2018. PMID: 30211312


  11. Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. JCO precision oncology 2018. PMID: 32914002


  12. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute 2018. PMID: 29659933


  13. Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research 2018. PMID: 29311117


  14. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein engineering, design & selection : PEDS 2018. PMID: 29301020


  15. Peters BA, Park JW, Drmanac R. Pure CTCs, advanced WGS, and precise personalized combination therapies. Oncoscience 2017. PMID: 28966939


  16. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer research 2017. PMID: 28811315


  17. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA oncology 2017. PMID: 27832260


  18. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer chemotherapy and pharmacology 2017. PMID: 28233053


  19. Pugia M, Magbanua MJM, Park JW. Automated Microfluidic Filtration and Immunocytochemistry Detection System for Capture and Enumeration of Circulating Tumor Cells and Other Rare Cell Populations in Blood. Methods in molecular biology (Clifton, N.J.) 2017. PMID: 28819845


  20. Pugia M, Magbanua MJM, Park JW. Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration. Advances in experimental medicine and biology 2017. PMID: 28560671


  21. Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW. Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC). Methods in molecular biology (Clifton, N.J.) 2017. PMID: 28819853


  22. Lee JS, Magbanua MJM, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast cancer research and treatment 2016. PMID: 27761678


  23. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. The New England journal of medicine 2016. PMID: 27406346


  24. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast cancer research and treatment 2015. PMID: 26520840


  25. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PloS one 2015. PMID: 26496203


  26. Magbanua MJ, Das R, Polavarapu P, Park JW. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget 2015. PMID: 26378808


  27. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, Esserman L, Park JW, van 't Veer LJ. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast cancer research : BCR 2015. PMID: 26021444


  28. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC cancer 2015. PMID: 25884197


  29. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 25712686


  30. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2014. PMID: 25524311


  31. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast cancer research and treatment 2014. PMID: 25432738


  32. Magbanua MJ, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer metastasis reviews 2014. PMID: 24867683


  33. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 2014. PMID: 25030168


  34. Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Melisko M, Park JW. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genomics data 2014. PMID: 26484071


  35. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Volume 32 of Issue 14. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 24711549


  36. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer research 2013. PMID: 24142343


  37. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British journal of cancer 2013. PMID: 24022191


  38. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods (San Diego, Calif.) 2013. PMID: 23896286


  39. Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (London, England) 2013. PMID: 23631502


  40. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Volume 19 of Issue 11. Clinical cancer research : an official journal of the American Association for Cancer Research 2013. PMID: 23470967


  41. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer research 2012. PMID: 23135909


  42. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast cancer research and treatment 2012. PMID: 22941572


  43. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC cancer 2012. PMID: 22373240


  44. Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012. PMID: 22323773


  45. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast cancer research and treatment 2011. PMID: 22198412


  46. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2011. PMID: 22003129


  47. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast cancer research and treatment 2011. PMID: 21597921


  48. Park JW. Disseminated tumor cells: the method is the message. Breast cancer research and treatment 2010. PMID: 20700647


  49. Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J. Characterization of a novel, trastuzumab resistant human breast cancer cell line. Frontiers in bioscience (Elite edition) 2010. PMID: 20036907


  50. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19841327


  51. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clinical cancer research : an official journal of the American Association for Cancer Research 2009. PMID: 19723649


  52. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC genomics 2009. PMID: 19619282


  53. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008. PMID: 19047117


  54. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clinical breast cancer 2008. PMID: 18952552


  55. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano letters 2008. PMID: 18712930


  56. Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer letters 2007. PMID: 18096313


  57. Esserman LJ, Shieh Y, Park JW, Ozanne EM. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert review of molecular diagnostics 2007. PMID: 17892362


  58. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007. PMID: 17704416


  59. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncology 2007. PMID: 17652269


  60. Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Molecular pharmacology 2007. PMID: 17392524


  61. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU international 2007. PMID: 17407512


  62. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magnetic resonance imaging 2007. PMID: 17371720


  63. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology 2006. PMID: 17018695


  64. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer research 2006. PMID: 16818648


  65. Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology 2006. PMID: 16723630


  66. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer research 2006. PMID: 16540680


  67. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer research 2006. PMID: 16510602


  68. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer research 2005. PMID: 16357174


  69. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Experimental neurology 2005. PMID: 16197944


  70. Krauze MT, Mcknight TR, Yamashita Y, Bringas J, Noble CO, Saito R, Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain research. Brain research protocols 2005. PMID: 16181805


  71. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16027440


  72. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16027439


  73. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast cancer research and treatment 2005. PMID: 15868444


  74. Melisko ME, Kunwar S, Prados M, Berger MS, Park JW. Brain metastases of breast cancer. Expert review of anticancer therapy 2005. PMID: 15877523


  75. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in oncology 2004. PMID: 15717745


  76. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert opinion on therapeutic targets 2004. PMID: 15268628


  77. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 2004. PMID: 15221993


  78. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical cancer research : an official journal of the American Association for Cancer Research 2004. PMID: 15173097


  79. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clinical cancer research : an official journal of the American Association for Cancer Research 2004. PMID: 15173098


  80. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. Journal of neuro-oncology 2004. PMID: 15174514


  81. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer research 2004. PMID: 15059914


  82. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003. PMID: 14643297


  83. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer research 2003. PMID: 12810643


  84. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast cancer research : BCR 2002. PMID: 12052251


  85. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clinical cancer research : an official journal of the American Association for Cancer Research 2002. PMID: 11948130